Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (373)	5/12/1999 4:48:00 PM
From: Biomaven	Respond to of 3158

Maybe we'll find out what CNTO was asking. The only numbers floating around were totals, which were hard to interpret because I don't know if they included CNTO's large slug of convertible debentures or not. CNTO at around 40 is by far the cheapest of the bigger biotechs. As someone commented, it always trades as if some dire news was about to be announced tomorrow. One issue of course is whether it is now "in play." J&J would have been a very good fit because of the stent/ReoPro link, but others might be eyeing it now instead. Peter

To: LLCF who wrote (373)	5/13/1999 1:23:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 3158

The WSJ today implied that this might only be a "pause" in the CNTO/J&J story, and that other suitors might be waiting in the wings. As we discussed on the Derivatives thread, rumors abounding today - BGEN up sharply on no news, big call activity in MLNM. BGEN would be a luscious prize for any of the big pharma. MLNM is more problematic because of its big existing ties to Bayer, Monsanto, etc. I'd be somewhat surprised and definitely sorry to see it munched. Peter